
Torii gets Japanese marketing rights to HIV therapy from parent Japan Tobacco; Rights returned
Executive Summary
Japan Tobacco Inc. has licensed its Japanese pharma subsidiary Torii Pharmaceutical Co. Ltd. exclusive rights to market a single-tablet HIV treatment containing JTK303 (elvitegravir) in Japan.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com